Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
DOI:
https://doi.org/10.3889/oamjms.2019.370Keywords:
Oral rivaroxaban, Standard therapy, Acute venous thromboembolism, Vietnamese patientsAbstract
BACKGROUND: Direct oral anticoagulant-rivaroxaban may provide a simple, fixed-dose therapy for the management of hospital-acquired, acute venous thromboembolism (VTE) and for extended treatment, its use could skip lab observation and/or parenteral treatment.
AIM: Compare the efficacy and safety (EAS) of RIV vs. standard therapy (SDTD) in a cohort of Vietnamese patients diagnosed with symptomatic, acute VTE.
METHODS: An open-label, case-control, prospective study was conducted to check the efficacy and safety (EAS) of oral rivaroxaban (RIV) alone (15 mg 2 times/day for 3 weeks, then 20 mg 1 time/day) in a comparison to the standard therapy (STDT) (enoxaparin 1.0 mg/kg 2 times/day combining with vitamin K antagonist). Patients were treated for 6 months and followed-up for suspect reoccurring VTE and bleeding.
RESULTS: A total 187 patients were enrolled into study. 83 were provided rivaroxaban and 104 received enoxaparin overlapping with vitamin K antagonist (VKAs). Recurrent VTE occurred in 3 (3.6%) rivaroxaban-received patients compared with 5 (4.8%) standard-treatment received patients (OR: 0.74, 95% CI, 0.17 to 3.20, p > 0.05). Major bleeding events were found in 1 (1,8%) and 4 (3.9%) cases in the RIV treated and STDT cohort, respectively (OR: 0.30, 95% CI, 0.03 to 2.76, p > 0.05).
CONCLUSION: The finding of this study in Vietnamese patients with acute VTE presented comparable EAS profile with RIV versus STDT, consistent with those found in global population.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Næss IA, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007; 5(4):692-9. https://doi.org/10.1111/j.1538-7836.2007.02450.x PMid:17367492
Spencer FA, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009; 28(4):401-9. https://doi.org/10.1007/s11239-009-0378-3 PMid:19629642 PMCid:PMC3248815
Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost. 2011; 9(1):85-91. https://doi.org/10.1111/j.1538-7836.2010.04108.x PMid:20942850
Group JJW. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011; 75(5):1258-81. https://doi.org/10.1253/circj.CJ-88-0010 PMid:21441695
Edwards MS, et al. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012; 14(2):e31-e47. https://doi.org/10.1111/j.1463-1318.2011.02765.x PMid:21848897 PMCid:PMC3562494
Sarich TC, et al. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci. 2013; 1291(1):42-55. https://doi.org/10.1111/nyas.12136 PMid:23701516
Investigators E, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. https://doi.org/10.1056/NEJMoa1007903 PMid:21128814
Prins MH, Lensing AW. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thrombosis journal. 2013; 11(1):13. https://doi.org/10.1186/1477-9560-11-13 PMid:23829521 PMCid:PMC3710481
Authors/Task Force Members, Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2014. 35(43):3033-69.
Wang Y, et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal. 2013; 11(25). https://doi.org/10.1186/1477-9560-11-25 PMid:24341332 PMCid:PMC3896794
Prins MH, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014; 1(1):e37-46. https://doi.org/10.1016/S2352-3026(14)70018-3
Coleman CI, et al. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. J Thromb Thrombolysis. 2018; 46(3):339-345. https://doi.org/10.1007/s11239-018-1695-1 PMid:29881958
Jr, A.F., et al., A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991; 151(5):933-8. https://doi.org/10.1001/archinte.1991.00400050081016
Heit JA, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6):809-15. https://doi.org/10.1001/archinte.160.6.809 PMid:10737280
Caiafa JS, et al. Managing venous thromboembolism in Latin American patients: emerging results from the Brazilian Registry. Semin Thromb Hemost. 2002; 28(Suppl 3):47-50. https://doi.org/10.1055/s-2002-34076 PMid:12232824
Goldhaber SZ, Dunn K, Mac Dougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest. 2000; 118(6):1680-4. https://doi.org/10.1378/chest.118.6.1680 PMid:11115458
Prins MH, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1):21. https://doi.org/10.1186/1477-9560-11-21 PMid:24053656 PMCid:PMC3850944
Büller HR, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012; 379(9811):123-9. https://doi.org/10.1016/S0140-6736(11)61505-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 My Hanh Bui, Nguyen Truong Son, Pham Thanh Viet, Nguyen Hoang Hiep, Toi Chu Dinh (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0